Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

A new review published in JAMA highlights the current diagnosis and treatment of pulmonary sarcoidosis.The review authors performed online searches of PubMed and OVID from 2015 to 2021 and ...

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study ...

The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in North America, Europe and Japan. The trial design will incorporate a forced steroid taper.

Unlike sarcoidosis, disease involvement is more pronounced at the lung bases. In the early stages of interstitial pulmonary fibrosis, ill-defined or ground glass opacities may occur diffusely or ...

Response from Arthur Kavanaugh, MD. Certainly, patients can have sarcoidosis without having pulmonary involvement, although this is the case in less than 10% of sarcoid patients.

It affects about 1 in 10,000 people in the UK, according the charity Sarcoidosis UK. As well as the lungs it can also affect the skin, eyes, joints, nervous system, heart and other parts of the body.

The pulmonary sarcoidosis treatment landscape is poised for substantial transformation in the coming years, with the 7MM market expected to witness considerable growth by 2032. This expansion is ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

Sarcoidosis has rarely been reported with polycythemia vera (PV), an acquired myeloproliferative neoplasm characterized by mutant Janus kinase 2 ... and mild improvement of pulmonary sarcoidosis.

Results from a phase 1/2 study (ClinicalTrials Identifier: NCT03824392) in patients with pulmonary sarcoidosis showed that ATYR1923 was safe and well tolerated, with no drug-related adverse events.